Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain CLVS message board posts where the ticker symbol CLVS has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest CLVS SEC Filings

Filings Format Description Filing Date File/Film Number
S-8  Documents Securities to be offered to employees in employee benefit plans
Acc-no: 0001193125-18-236694 (33 Act)  Size: 67 KB
2018-08-02 333-226523
18988970
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001558370-18-006188 (34 Act)  Size: 8 MB
2018-08-02 001-35347
18987591
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001157523-18-001649 (34 Act)  Size: 116 KB
2018-08-01 001-35347
18984864
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001306923-18-000015 (34 Act)  Size: 54 KB
2018-06-25 005-86488
18916639
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-017650 Size: 8 KB
2018-06-21
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-017648 Size: 8 KB
2018-06-21
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001144204-18-035151 (34 Act)  Size: 161 KB
2018-06-21 005-86488
18911897
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-015794 Size: 9 KB
2018-06-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-015791 Size: 8 KB
2018-06-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-015788 Size: 8 KB
2018-06-08
More CLVS SEC Filings


Related news from
Fri, 10 Aug 2018
16:35:02 +0000
Puma Biotechnology: Recent Developments and Recommendations
In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.
Fri, 10 Aug 2018
15:00:48 +0000
How Puma Biotechnology Performed in Q2 2018
Puma Biotechnology (PBYI) released its second-quarter earnings results on August 9. It reported net revenue of $117.3 million in the first half of 2018. Puma Biotechnology’s revenue came primarily from its sales of Nerlynx.
Thu, 09 Aug 2018
18:30:02 +0000
Here’s How Exelixis Is Financially Positioned Now
Exelixis (EXEL) generated net revenues of $186.1 million in the second quarter of 2018 compared to $99 million in the second quarter of 2017. In the first half of 2018, Exelixis reported revenues of $399.8 million compared to $179.9 million in the first half of 2017. In the first half of 2018, Exelixis generated revenues of $280.1 million, reflecting ~92% YoY (year-over-year) growth.
Thu, 09 Aug 2018
15:28:55 +0000
Analyst Recommendations for Exelixis in August
In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, which was a ~66% YoY (year-over-year) growth. Exelixis’s net product revenues grew 9% sequentially in the second quarter. In the second quarter, Ipsen, Exelixis’s partner, generated cumulative revenues of $150 million from sales of cabozantinib.
Thu, 09 Aug 2018
12:04:22 +0000
See what the IHS Markit Score report has to say about Clovis Oncology Inc.
Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold CLVS had net inflows of $279 million over the last one-month.
Wed, 08 Aug 2018
12:00:00 +0000
Clovis Oncology Announces First Patient Enrolled in the Phase 3 ATHENA Trial
Trial to Evaluate the Combination of Rubraca® and OPDIVO® in Patients with Advanced Ovarian Cancer
Fri, 03 Aug 2018
20:09:47 +0000
Tesaro CEO Says Its Drug 'Will Get There' — Analysts Strongly Disagree
Tesaro stock crashed to a four-year low Friday after the biotech cut its 2018 outlook and analysts suggested its key drug, Zejula, is struggling to gain traction in the U.S.
Fri, 03 Aug 2018
17:30:06 +0000
Edited Transcript of CLVS earnings conference call or presentation 1-Aug-18 8:30pm GMT
Q2 2018 Clovis Oncology Inc Earnings Call
Fri, 03 Aug 2018
15:20:03 +0000
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Beat
Clovis (CLVS) misses bottom-line estimates in the second quarter but beats on the top line. Rubraca sales increase.
Thu, 02 Aug 2018
16:00:00 +0000
Boulder biotech wants to settle with the SEC for $20 million
Clovis Oncology Inc. said it wants to settle an investigation by the Securities and Exchange Commission for $20 million. In yesterday's second-quarter earnings report, the Boulder biotech said it "recorded a one-time charge of $20 million related to an agreement in principle reached with the S.E.C. that, if approved by the S.E.C. and the U.S. District Court where the settlement is to be filed, would resolve the S.E.C.’s investigation related to rociletinib." The SEC was interested in rociletinib, which Clovis was developing as a proposed lung cancer drug.
Wed, 01 Aug 2018
23:10:11 +0000
Clovis Oncology (CLVS) Reports Q2 Loss, Tops Revenue Estimates
Clovis (CLVS) delivered earnings and revenue surprises of -40.58% and 1.63%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Wed, 01 Aug 2018
22:05:52 +0000
Clovis: 2Q Earnings Snapshot
On a per-share basis, the Boulder, Colorado-based company said it had a loss of $1.94. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Wed, 01 Aug 2018
20:05:00 +0000
Clovis Oncology Announces Second Quarter 2018 Operating Results
BOULDER, Colo.-- -- $23.8M in Rubraca ® sales for the second quarter of 2018 compared to $14.6M for Q2 2017 Rubraca approved in U.S. on April 6, 2018 for expanded ovarian cancer maintenance treatment indication Rubraca granted Marketing Authorization by European Commission on May 29 for treatment of recurrent ovarian cancer EMA validated EU application to include ovarian cancer maintenance treatment ...
Fri, 27 Jul 2018
12:20:00 +0000
Today's Research Reports on Trending Tickers: Amgen and Clovis Oncology
NEW YORK, NY / ACCESSWIRE / July 27, 2018 / U.S. equities finished moderately lower on Thursday, pressured by sharp losses in tech stocks as Facebook posted its biggest daily drop ever after a disappointing ...
Wed, 25 Jul 2018
17:31:00 +0000
Buy These 3 Risky Biotech Stocks
There's been a lot of talk on the Street about the biotech sector and how drug makers haven't been bringing the heat in 2018. Just six biotech company IPO launches hit this last week. Two new biotech companies are poised to go public this week.
Wed, 25 Jul 2018
12:27:43 +0000
What Clovis’s Bottom Line Is Expected to Look Like In Q2 2018
Clovis Oncology’s (CLVS) selling, general, and administrative expenses are expected to increase by 12.48% from $36.15 million in the second quarter of 2017 to $40.66 million in the second quarter of 2018. Clovis Oncology is expected to have a net income of -$84.85 million in the second quarter of 2018 compared to a net income of -$175.39 million in the second quarter of 2017. Of the nine analysts covering Clovis Oncology in July, seven have given the stock “buy” or higher ratings, and two have given it “hold” ratings.
Wed, 25 Jul 2018
12:27:43 +0000
What to Expect from Clovis Oncology’s Q2 2018 Earnings
Clovis Oncology (CLVS), a biopharmaceutical company focused on developing and bringing to market innovative anticancer agents, is expected to report its second-quarter earnings on August 1. Clovis’s development programs are targeted at treating specific subsets of cancer populations. Clovis’s Rubraca is targeted at treating adult patients with deleterious BRCA mutation epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Wed, 18 Jul 2018
12:00:00 +0000
Clovis Oncology to Announce Second Quarter 2018 Financial Results and Host Webcast Conference Call on August 1
Clovis Oncology, Inc. will announce its second quarter 2018 financial results on Wednesday, August 1, 2018, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m.
Fri, 06 Jul 2018
13:23:01 +0000
Clovis Gets EU Acceptance for Rubraca Label Expansion Filing
Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "VF is an awesome community of bright, serious, passionate and involved individual investors. Information is well organized into fine-grained topics and discussions are always on topic and relevant. People here certainly know what value is and this site itself is a great reflection of that. I feel honored and privileged to have found such a great resource and to be part of it!" more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards